Contributions
Abstract: P331
Type: Poster
Abstract Category: Clinical aspects of MS - 4 Natural course
Objective: To explore the conversion to secondary progressive multiple sclerosis (SPMS) in multiple sclerosis treated-patients seen from the first relapse and followed 18 years.
Methods: All patients that began treatment with Diseases Modifying Therapies (DMTs), between 1995 and 2002, have been prospectively followed. Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) were obtained to calculate disability. Kaplan-Meier Survival analysis was used to estimate time for reaching EDSS=3.0, conversion to SPMS, EDSS=6.0, and time between the beginning of SPMS and EDSS=6.0. A Cox multivariate regression analysis was used to explore prognostic factors.
Results: 204 patients have been uninterruptedly treated for 13 years; initially with first-line DMTs, and in 88 patients with second-line therapies because treatment failure (43.1%). 53.4% of patients reaching an EDSS=3.0, 36.3% converted to SPMS; and 17.8% reached an EDSS=6.0 (estimated time: 14.1 years, 19.9 years and 17.2 years, respectively). A multifocal syndrome, an age older than 34 years at the beginning; and treatment failure, independently predicted the conversion to SPMS. Reaching an EDSS of 3.0 in less than 7 years predicted an early conversion to SPMS. All these variables did not influence the time to reach an EDSS of 6.0 once a patient was diagnosed of SPMS, which was 9.0 years.
Interpretation: A reduction in the rate of conversion to SPMS and a lower cumulated disability has been observed in our cohort with the current escalating treatment strategy. However, patients that converted to SPMS had similar characteristics to those of classical natural history studies.
Disclosure:
B Casanova have received fees and grant form Sanofi Novarits, Roche, TEVA, Merck, and Almirall.
FC Miralles have received fees and grant form Sanofi Novarits, Roche, TEVA, Merck, and Almirall.
F Gascón, C Alcalá, A. Navarré, A. Bernad, I. Boscá, M Escutia, and S. Gil-Perotin, have nor confict of interests to declarer
F Ciret deceassed.
Abstract: P331
Type: Poster
Abstract Category: Clinical aspects of MS - 4 Natural course
Objective: To explore the conversion to secondary progressive multiple sclerosis (SPMS) in multiple sclerosis treated-patients seen from the first relapse and followed 18 years.
Methods: All patients that began treatment with Diseases Modifying Therapies (DMTs), between 1995 and 2002, have been prospectively followed. Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) were obtained to calculate disability. Kaplan-Meier Survival analysis was used to estimate time for reaching EDSS=3.0, conversion to SPMS, EDSS=6.0, and time between the beginning of SPMS and EDSS=6.0. A Cox multivariate regression analysis was used to explore prognostic factors.
Results: 204 patients have been uninterruptedly treated for 13 years; initially with first-line DMTs, and in 88 patients with second-line therapies because treatment failure (43.1%). 53.4% of patients reaching an EDSS=3.0, 36.3% converted to SPMS; and 17.8% reached an EDSS=6.0 (estimated time: 14.1 years, 19.9 years and 17.2 years, respectively). A multifocal syndrome, an age older than 34 years at the beginning; and treatment failure, independently predicted the conversion to SPMS. Reaching an EDSS of 3.0 in less than 7 years predicted an early conversion to SPMS. All these variables did not influence the time to reach an EDSS of 6.0 once a patient was diagnosed of SPMS, which was 9.0 years.
Interpretation: A reduction in the rate of conversion to SPMS and a lower cumulated disability has been observed in our cohort with the current escalating treatment strategy. However, patients that converted to SPMS had similar characteristics to those of classical natural history studies.
Disclosure:
B Casanova have received fees and grant form Sanofi Novarits, Roche, TEVA, Merck, and Almirall.
FC Miralles have received fees and grant form Sanofi Novarits, Roche, TEVA, Merck, and Almirall.
F Gascón, C Alcalá, A. Navarré, A. Bernad, I. Boscá, M Escutia, and S. Gil-Perotin, have nor confict of interests to declarer
F Ciret deceassed.